Cargando…

Determinants for Acceptance of COVID-19 Vaccine in Nigeria

Background: The coronavirus disease 2019 (COVID-19) pandemic heralded an unprecedented race to the development of several vaccine candidates at record speeds never seen in global health. Within nine months, Pfizer-BioNTech’s COVID-19 vaccine was approved by the United States FDA. Unfortunately, whil...

Descripción completa

Detalles Bibliográficos
Autores principales: Eze, Ugochukwu A, Ndoh, Kingsley I, Ibisola, Babalola A, Onwuliri, Chinemerem D, Osiyemi, Adenekan, Ude, Nnamdi, Chime, Amalachukwu A, Ogbor, Eric O, Alao, Adegboyega O, Abdullahi, Ashiru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695669/
https://www.ncbi.nlm.nih.gov/pubmed/34963828
http://dx.doi.org/10.7759/cureus.19801
_version_ 1784619628566151168
author Eze, Ugochukwu A
Ndoh, Kingsley I
Ibisola, Babalola A
Onwuliri, Chinemerem D
Osiyemi, Adenekan
Ude, Nnamdi
Chime, Amalachukwu A
Ogbor, Eric O
Alao, Adegboyega O
Abdullahi, Ashiru
author_facet Eze, Ugochukwu A
Ndoh, Kingsley I
Ibisola, Babalola A
Onwuliri, Chinemerem D
Osiyemi, Adenekan
Ude, Nnamdi
Chime, Amalachukwu A
Ogbor, Eric O
Alao, Adegboyega O
Abdullahi, Ashiru
author_sort Eze, Ugochukwu A
collection PubMed
description Background: The coronavirus disease 2019 (COVID-19) pandemic heralded an unprecedented race to the development of several vaccine candidates at record speeds never seen in global health. Within nine months, Pfizer-BioNTech’s COVID-19 vaccine was approved by the United States FDA. Unfortunately, while these advances were ongoing, there was a burgeoning epidemic of disinformation about the virus and the vaccines that affected the willingness of people, especially minority groups, to get vaccinated. In Nigeria, this wave of vaccine hesitancy was happening against the backdrop of landmark pharmaceutical litigations such as the 2007 Pfizer trovafloxacin lawsuit in the country. Aim: To assess the determinants of the COVID-19 vaccine's acceptability among Nigerians. Materials and methods: Following ethical approval, a population-based cross-sectional study was conducted from November 2020 to January 2021 using an adapted pretested, self-administered questionnaire originally designed by Amyn Malik and colleagues who conducted a similar study at Yale University School of Public Health. The participants were recruited through simple random sampling using a list of community and corporate sites obtained from Google Maps in the three regional zones of Nigeria (north, east, and west) in diverse occupational and residential settings. Information obtained includes socio-demographics, medical history related to COVID-19, level of knowledge, risk perception, and attitudes toward COVID-19 and the vaccines. Descriptive and inferential statistics were done, and results were summarized into percentages and associations. The level of statistical significance was set at a p-value of <0.05. Using the open EpiR package (Emory), we determined a minimum of 340 participants for a statistical power of 80%. Results: A total of 358 responses were obtained out of the 120 questionnaires distributed in each of the three regions, of which 189 (53%) were females. The mean age of respondents was 32 years (±11.2 SD). About 75% of the participants had at least a college education. The majority (66.2%) of the participants were willing to accept the approved vaccine. The mean risk perception score for COVID-19 was 5.1 (±2.2 SD) out of 10, while the mean COVID-19 symptom knowledge score was 8.6 (±4.1 SD) out of 19. Variables such as being male, identifying as Christian, Hausa ethnicity, and living in northern Nigeria had a statistically significant relationship with the willingness to get vaccinated. Conclusion: Over 60% of Nigerians are willing to take the COVID-19 vaccines if recommended by health workers. We found male gender, religion, ethnicity, and geographical location to positively influence the willingness of Nigerians to get vaccinated against COVID-19. Health workers should be supported to go beyond the confines of the hospital to educate the general public in schools, marketplaces, churches, and corporate organizations on the efficacy and safety of the approved vaccines.
format Online
Article
Text
id pubmed-8695669
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-86956692021-12-27 Determinants for Acceptance of COVID-19 Vaccine in Nigeria Eze, Ugochukwu A Ndoh, Kingsley I Ibisola, Babalola A Onwuliri, Chinemerem D Osiyemi, Adenekan Ude, Nnamdi Chime, Amalachukwu A Ogbor, Eric O Alao, Adegboyega O Abdullahi, Ashiru Cureus Preventive Medicine Background: The coronavirus disease 2019 (COVID-19) pandemic heralded an unprecedented race to the development of several vaccine candidates at record speeds never seen in global health. Within nine months, Pfizer-BioNTech’s COVID-19 vaccine was approved by the United States FDA. Unfortunately, while these advances were ongoing, there was a burgeoning epidemic of disinformation about the virus and the vaccines that affected the willingness of people, especially minority groups, to get vaccinated. In Nigeria, this wave of vaccine hesitancy was happening against the backdrop of landmark pharmaceutical litigations such as the 2007 Pfizer trovafloxacin lawsuit in the country. Aim: To assess the determinants of the COVID-19 vaccine's acceptability among Nigerians. Materials and methods: Following ethical approval, a population-based cross-sectional study was conducted from November 2020 to January 2021 using an adapted pretested, self-administered questionnaire originally designed by Amyn Malik and colleagues who conducted a similar study at Yale University School of Public Health. The participants were recruited through simple random sampling using a list of community and corporate sites obtained from Google Maps in the three regional zones of Nigeria (north, east, and west) in diverse occupational and residential settings. Information obtained includes socio-demographics, medical history related to COVID-19, level of knowledge, risk perception, and attitudes toward COVID-19 and the vaccines. Descriptive and inferential statistics were done, and results were summarized into percentages and associations. The level of statistical significance was set at a p-value of <0.05. Using the open EpiR package (Emory), we determined a minimum of 340 participants for a statistical power of 80%. Results: A total of 358 responses were obtained out of the 120 questionnaires distributed in each of the three regions, of which 189 (53%) were females. The mean age of respondents was 32 years (±11.2 SD). About 75% of the participants had at least a college education. The majority (66.2%) of the participants were willing to accept the approved vaccine. The mean risk perception score for COVID-19 was 5.1 (±2.2 SD) out of 10, while the mean COVID-19 symptom knowledge score was 8.6 (±4.1 SD) out of 19. Variables such as being male, identifying as Christian, Hausa ethnicity, and living in northern Nigeria had a statistically significant relationship with the willingness to get vaccinated. Conclusion: Over 60% of Nigerians are willing to take the COVID-19 vaccines if recommended by health workers. We found male gender, religion, ethnicity, and geographical location to positively influence the willingness of Nigerians to get vaccinated against COVID-19. Health workers should be supported to go beyond the confines of the hospital to educate the general public in schools, marketplaces, churches, and corporate organizations on the efficacy and safety of the approved vaccines. Cureus 2021-11-22 /pmc/articles/PMC8695669/ /pubmed/34963828 http://dx.doi.org/10.7759/cureus.19801 Text en Copyright © 2021, Eze et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Preventive Medicine
Eze, Ugochukwu A
Ndoh, Kingsley I
Ibisola, Babalola A
Onwuliri, Chinemerem D
Osiyemi, Adenekan
Ude, Nnamdi
Chime, Amalachukwu A
Ogbor, Eric O
Alao, Adegboyega O
Abdullahi, Ashiru
Determinants for Acceptance of COVID-19 Vaccine in Nigeria
title Determinants for Acceptance of COVID-19 Vaccine in Nigeria
title_full Determinants for Acceptance of COVID-19 Vaccine in Nigeria
title_fullStr Determinants for Acceptance of COVID-19 Vaccine in Nigeria
title_full_unstemmed Determinants for Acceptance of COVID-19 Vaccine in Nigeria
title_short Determinants for Acceptance of COVID-19 Vaccine in Nigeria
title_sort determinants for acceptance of covid-19 vaccine in nigeria
topic Preventive Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695669/
https://www.ncbi.nlm.nih.gov/pubmed/34963828
http://dx.doi.org/10.7759/cureus.19801
work_keys_str_mv AT ezeugochukwua determinantsforacceptanceofcovid19vaccineinnigeria
AT ndohkingsleyi determinantsforacceptanceofcovid19vaccineinnigeria
AT ibisolababalolaa determinantsforacceptanceofcovid19vaccineinnigeria
AT onwulirichinemeremd determinantsforacceptanceofcovid19vaccineinnigeria
AT osiyemiadenekan determinantsforacceptanceofcovid19vaccineinnigeria
AT udennamdi determinantsforacceptanceofcovid19vaccineinnigeria
AT chimeamalachukwua determinantsforacceptanceofcovid19vaccineinnigeria
AT ogborerico determinantsforacceptanceofcovid19vaccineinnigeria
AT alaoadegboyegao determinantsforacceptanceofcovid19vaccineinnigeria
AT abdullahiashiru determinantsforacceptanceofcovid19vaccineinnigeria